Clintrax Global Named as Finalist for Triangle Business Journal's 2016 Life Sciences Awards

The Life Sciences Awards recognize both individuals and research organizations that are breaking ground in this broad field, which includes biology, biotechnology, genomics, neuroscience, pharmacology and many other areas of focus. Clintrax is one of 17 finalists to qualify for this honor; an esteemed list which includes industry leaders such as Bayer Corporation and INC Research.

"We are proud to have been recognized by the Triangle Business Journal – and included among such august finalists — for this important achievement," commented Donald A. Deieso, PhD, Chairman and CEO of WCG. "North Carolina —and specifically its robust Research Triangle — is home to over 600 life science companies employing 60,000 individuals who are dedicated to the advancement of human health. We are honored not only to serve this mission, but to be an active member in this community."

Added Clintrax CEO Brandon Evans, "We founded Clintrax in order to help biopharmaceutical sponsors conduct clinical trials more efficiently, so that they could bring life-saving drugs to market faster. By simplifying and expediting the negotiation of clinical trial contracts, budgets and payments, we do just that. The recognition of Triangle Business Journal means the world to our employees, who come to work every day because they believe that we're truly making a difference." 

Finalists were selected based on the merit of key milestones achieved within the past year, as well as their unique and innovative contributions to the life sciences industry.

The winners of the 2016 Life Sciences Awards will be announced during a luncheon on May 26, 2016, which will be held at the Umstead Hotel & Spa in Cary, NC. For more information and a complete list of this year's Life Sciences Awards finalists, please visit http://www.bizjournals.com/triangle/news/.

About Clintrax Global 
Clintrax Global, Inc. specializes in the negotiation of clinical trial contracts and budgets between biopharmaceutical companies, contract research organizations (CROs) and investigator sites around the world. Clintrax also manages, executes, and tracks payments from the research sponsor to its associated research sites.

Founded by former biopharmaceutical and CRO attorneys, Clintrax Global has accelerated hundreds of clinical trials since its inception. Supported by technology-driven processes and a network of international attorneys who possess specialized and in-depth knowledge of local languages and regulations across 65 countries, Clintrax significantly reduces the amount of time devoted to the negotiation process.  For more information, please visit clintraxglobal.com.

About WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research. The industry's first Clinical Services Organization (CSO), WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protections.

WCG solutions include contract and budget negotiation, study start-up acceleration, regulatory and ethical review services, oversight of research involving gene therapy, and lab safety consulting. Powered by a suite of proprietary technologies, WCG solutions help clients to increase regulatory compliance and support the digital management of clinical trials. For more information, please visit http://www.wcgclinical.com or follow us on Twitter @WCGClinical.

Logo - http://photos.prnewswire.com/prnh/20140422/77410

SOURCE WIRB-Copernicus Group

Related Links

http://www.wcgclinical.com